Diamyd
Diamyd Uses, Dosage, Side Effects, Food Interaction and all others data.
Diamyd (recombinant human glutamic acid decarboxylase) is a vaccine being developed to treat insulin dependent type 1 diabetes.
The immune system of patients treated with Diamyd demonstrate an increase in the secretion of several immunomodulatory substances, dominated by regulatory cytokines, including IL5, IL13, IL10, IL17, IFN-a and TNF-a. Additionally, the activity of T-cells in response to GAD65 is increased with Diamyd therapy and subjects receiving Diamyd show an up regulation of cytokines in response to GAD65.
Trade Name | Diamyd |
Generic | rhGAD65 |
rhGAD65 Other Names | Recombinant human GAD65, Recombinant human glutamic acid decarboxylase |
Type | |
Groups | Investigational |
Therapeutic Class | |
Manufacturer | |
Available Country | |
Last Updated: | September 19, 2023 at 7:00 am |
Uses
Investigated for use/treatment in diabetes mellitus type 1.
Innovators Monograph
You find simplified version here Diamyd